IGF-1 and IGFBP-3 gene variants influence on serum levels and prostate cancer risk in African-Americans

Carcinogenesis

Volumn 28, Issue 10, 2007, Pages 2154-2159

  Hernandez, Wenndy ^a   Grenade, Cassandra ^b   Santos, Eunice R ^a   Bonilla, Carolina ^c   Ahaghotu, Chiledum ^d   Kittles, Rick A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HOWARD UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOSINE; GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TYROSINE;

5' UNTRANSLATED REGION; ADULT; AFRICAN AMERICAN; AGED; ALLELE; AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; BLOOD LEVEL; CANCER RISK; CARCINOGENESIS; CASE CONTROL STUDY; CHEMOLUMINESCENCE; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; IMMUNOCHEMISTRY; INHIBITION KINETICS; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; DISTRICT OF COLUMBIA; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TRANSCRIPTION, GENETIC; VARIATION (GENETICS);

EID: 35148882966     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm190     Document Type: Article

References (38)

1. Jemal,A. et al. (2007) Cancer statistics, 2007. CA Cancer J. Clin., 57, 43-66.
2. Moschos,S.J. et al. (2002) The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 63, 317-332.
3. Rosen,C.J. (1999) Serum insulin-like growth factors and insulin-like growth factor-binding proteins: Clinical implications. Clin. Chem. 45, 1384-1390.
4. Rotwein,P. et al. (1986) Organization and sequence of the human insulin-like growth factor I gene. Alternative RNA processing produces two insulin-like growth factor I precursor peptides. J. Biol. Chem. 261, 4828-4832.
5. Cohen,P. (2006) Overview of the IGF-I system. Horm Res., 65 (Suppl. 1), 3-8.
6. Hwa,V. et al. (1999) Insulin-like growth factor binding proteins: a proposed superfamily. Acta Paediatr. Suppl., 88, 37-45.
7. Cohick,W.S. et al. (1993) The insulin-like growth factors. Annu. Rev. Physiol., 55, 131-153.
8. Rietveld, I. et al. (2003) A polymorphism in the IGF-I gene influences the age-related decline in circulating total IGF-I levels. Eur. J. Endocrinol., 148, 171-175.
9. Kaklamani, V.G. et al. (1999) Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J. Clin. Oncol., 17, 3291-3298.
10. Cruickshank, J.K. et al. (2001) Epidemiology of the insulin-like growth factor system in three ethnic groups. Am J. Epidemiol., 154, 504-513.
11. Colangelo,L.A. et al. (2005) IGF-1, IGFBP-3, and nutritional factors in young black and white men: The CARDIA Male Hormone Study. Nutr. Cancer, 53, 57-64.
12. Yu,H. et al. (2000) Role of the insulin-like growth factor family in cancer development and progression. J. Natl Cancer Inst., 92 1472-1489.
13. Rietveld,I. et al. (2003) A polymorphic CA repeat in the promoter region of the insulin-like growth factor-I (IGF-I) gene. Eur. J. Epidemiol., 18, 191-193.
14. Schildkraut,J.M. et al. (2005) IGF1 (CA)19 repeat and IGFBP3 - 202 A/C genotypes and the risk of prostate cancer in Black and White men. Cancer Epidemiol. Biomarkers Prev., 14, 403-408.
15. Wong,H.L. et al. (2005) A new single nucleotide polymorphism in the insulin-like growth factor I regulatory region associates with eolorectal cancer risk in singapore chinese. Cancer Epidemiol. Bionmarkers Prev., 14, 144-151.
16. Cheng,I. et al. (2006) Common genetic variation in IGF1 and prostate cancer risk in the multiethnic cohort. J. Natl Cancer Inst. 98, 123-134.
17. Friedrichsen,D.M. et al. (2005) IGF-I and IGFBP-3 polymorphisms and risk of prostate cancer. Prostate, 65, 44-51.
18. Bonilla,C. et al. (2004) Admixture in the Hispanics of the San Luis Valley, Colorado, and its implications for complex trait gene mapping. Ann. Hum. Genet., 68, 139-153.
19. Hoggart,C.J. et al. (2004) Design and analysis of admixture mapping studies. Am J. Hum. Genet., 74, 965-978.
20. Shriver,M.D. et al. (2004) The genomic distribution of population substructure in four populations using 8,525 autosomal SNPs. Hum Genomics, 1, 274-286.
21. Shriver,M.D. et al. (2003) Skin pigmentation, biogeographical ancestry and admixture mapping. Hum Genet., 112, 387-399.
22. Morimoto,L.M. et al. (2005) Variation in plasma insulin-like growth factor-1 and insulin-like growth factor binding protein-3: genetic factors. Cancer Epidemiol. Biomarkers Prev., 14, 1394-1401.
23. Pritchard,J.K. et al. (2000) Inference of population structure using multilocus genotype data. Genetics, 155, 945-959.
24. Deal,C. et al. (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: Correlation with serum levels and interaction with known regulators. J. Clin. Endocrinol. Metab., 86, 1274-1290.
25. Allen,N.E. et al. (2002) Serum insulin-like growth factor I (IGF-I) concentration in men is not associated with the cytosine-adenosine repeat polymorphism of the IGF-I gene. Cancer Epidemiol. Biomarkers Prev., 11, 319-320.
26. Chen,C. et al. (2006) Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol. Biomarkers Prev., 15, 2461-2466.
27. Li,L. et al. (2004) No association between a tetranucleotide repeat polymorphism of CYP19 and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 13, 2280-2281.
28. Neuhausen,S.L. et al. (2005) Prostate cancer risk and IRS1, IRS2, IGF1, and INS polymorphisms: Strong association of IRS1 G972R variant and cancer risk. Prostate, 64, 168-174.
29. Cheng,I. et al. (2006) Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: The multiethnic cohort. Cancer Epidemiol. Biomarkers Prev., 15, 1993-1997.
30. Peng,L. et al. (2004) Identification of a functional vitamin D response element in the human insulin-like growth factor binding protem-3 promoter. Mol. Endocrinol., 18, 1109-1119.
31. De Benedetti,F. et al. (1997) Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J. Clin. Invest., 99, 643-650.
32. De Benedetti,F. et al. (2001) Effect of IL-6 on IGF binding protein-3: A study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology, 142, 4818-4826.
33. Pold,M. et at. (2004) Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer. Cancer Res., 64, 6549-6555.
34. Brabant,G. et al. (2003) Serum insulin-like growth factor I reference values for an automated chemiluminescence immumnoassay system: results from a multicenter study. Horm Res., 60, 53-60.
35. Chestnut,R.E. et al. (2002) Evaluation of total IGF-I assay methods using samples from Type I and Type II diabetic patients. J. Immunol. Methods, 259, 11-24.
36. Platz,E.A. et al. (1999) Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol. Biomarkers Prev., 8, 1107-1110.
37. l7 McGreevy,K.M. et al. (2007) Impact of nutrients on insulin-like growth factor-I, insulin-like growth factor binding protein-3 and their ratio in African American and white males. Public Health Nutr., 10, 97-105.
38. Chan,J.M. et al. (2002) Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J. Natl Cancer Inst., 94, 1099-1106.